In an article published on October 13th, 2020, Biostock interviewed James Sheridan, Head of Sales and Marketing, EMEA, APAC at Integrum AB, and Patrick Treacy, CEO at Onkos Surgical.
The article outlines Integrum’s leading position in the bone-anchored prosthetics market, the commercial breakthrough through its framework agreement with the US Military, the Pre-market Approval application in the United States, and the close collaboration with leading, well-renowned hospitals and teaching institutions worldwide.
In the interview, Mr. Sheridan discusses Integrum’s strategy towards expanding in key markets outside the US and the short-term goals for the company.
An essential facet of Integrum’s strategy is to increase collaboration with the key centers in the major markets.” – James Sheridan, Head of Sales and Marketing EMEA, APAC, Integrum
Early this year, Integrum and Onkos Surgical announced their commercial partnership to further drive bone -anchored prosthetics in the US Market. Patrick Treacy, CEO of Onkos Surgical, elaborates on this collaboration. In the midst of the global pandemic, Onkos Surgical has introduced the OPRA™ Implant System to Emory University, and most recently, the University of Southern California.
The interview also discusses Onkos Surgical’s vision to expand the availability of the OPRA™ Implant System; this fueled by its unique regulatory status, the gaping patient need for such a system, and the extremely positive market response thus far.
“Integrum has a tremendous competitive advantage, they have the only FDA-approved device and as such, their device is the only legally marketable device. So Integrum have a very strong regulatory position in comparison to competitors.” – Patrick Treacy, CEO, Onkos Surgical
Read the interview here.
Biostock is the Nordic region’s leading digital news and analysis service focussing on companies in the Life Science sector. Biostock owns extensive international reach through its exponentially growing network and partnerships.